Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6441529 | 0.88 | EPHX2 (0.54) | EPHX2HTTSMN1; SMN2GAAHPGD | |
| SCHEMBL2798799 | 0.86 | CCR1 (0.58) | EPHX2HTTSMN1; SMN2GAAHPGD | |
| SCHEMBL6156258 | 0.85 | CCR1 (0.43) | EPHX2TSHRCCR1LMNANPC1 | |
| SCHEMBL6156266 | 0.85 | CCR1 (0.43) | EPHX2TSHRCCR1LMNANPC1 | |
| SCHEMBL6758368 | 0.85 | CCR1 (0.43) | EPHX2TSHRCCR1LMNANPC1 | |
| SCHEMBL4634837 | 0.84 | HSD11B1 (0.54) | HTTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL6442642 | 0.83 | CCR1 (0.55) | EPHX2HTTSMN1; SMN2GAAHPGD | |
| SCHEMBL6443342 | 0.83 | POLB (0.60) | EPHX2HTTSMN1; SMN2GAAHPGD | |
| SCHEMBL6439747 | 0.83 | KDM4E (0.65) | EPHX2HTTSMN1; SMN2GAAHPGD | |
| SCHEMBL6155786 | 0.81 | CCR1 (0.42) | EPHX2TSHRMAPTCCR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534677-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | Pfizer Products Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040063759-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | claimed |
| WO-2004009550-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | claimed |
| EP-1534677-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | Pfizer Products Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063759-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2004009550-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063759-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | EPHX2 3153/4885HTT 4825/4885SMN1; SMN2 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.